扶正通络方对原发性肝癌患者临床疗效及免疫功能的影响

Effect of Fuzheng Tongluo Recipe on clinical efficacy and immune function in patients with primary liver cancer

目的探讨扶正通络方治疗原发性肝癌的临床疗效及免疫学影响。方法将2016年5月至2018年5月期间,本院收治的76例已明确诊断为原发性肝癌的患者作为研究对象,根据其入院时的病历号随机分为治疗组和对照组,每组38例。在常规对症治疗的基础上,对照组给予槐耳颗粒进行治疗,治疗组应用扶正通络方治疗,28d为1个疗程,共3个疗程。比较两组治疗前后的卡氏(KPS)评分、中医症候积分、中医证候疗效以及外周血中T淋巴细胞亚群(CD3+,CD4+,CD4+/CD8+)的水平变化情况。结果 与治疗前比较,治疗组在治疗后的中医证候积分显著降低,KPS评分显著升高,差异均有统计学意义(均P<0.05);两组治疗后,治疗组的中医证候积分及KPS评分改善程度显著优于对照组,差异均有统计学意义(均P<0.05);疗程结束后,对照组与治疗组的改善率分别为42.1%和71.1%,两组比较,差异有统计学意义(P<0.05);两组治疗后的CD3+、CD4+以及CD4+/CD8+均有所升高,且对照组明显优于对照组,差异均有统计学意义(均P<0.05)。结论 应用扶正通络方治疗原发性肝癌患者,能够较好地提升临床症状的改善率,有效地改善患者的生活质量、提升机体的免疫功能,值得临床推广和应用。

Objective To investigate the clinical efficacy and immunological effects of Fuzheng Tongluo Recipe in the treatment of primary liver cancer. Methods Sixty-six patients diagnosed with primary liver cancer in our hospital from May, 2016 to May, 2018 were randomly divided into a treatment group and a control group according to their medical records at admission , with 38 cases in each group. On the basis of conventional symptomatic treatment, the control group was treated with Qier granules, and the treatment group with Fuzheng Tongluo Recipe, 28 days for 1 treatment course, and for 3 courses. The Karst (KPS) score, TCM syndrome score, TCM syndrome effect, and T lymphocyte subsets (CD3+, CD4+, CD4+/CD8+) in peripheral blood were compared between the two groups. Results The TCM syndrome scores were significantly lower and the KPS score was significantly higher after than before the treatment in the treatment group (P < 0.05), and were better in the treatment group than in the control group after the treatment. After the treatment, the improvement rates of the control group and the treatment group were 42.1% and 71.1%, respectively (P < 0.05). After the treatment, the CD3+, CD4+, and CD4+/CD8+ increased in both groups, and were significantly better in the treatment group than in the control group (all P < 0.05). Conclusion Fuzheng Tongluo Recipe in the treatment of patients with primary liver cancer can improve their clinical symptoms, quality of life, and immune function, so it is worth for clinical promotion and application.